Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment

The 12/15 lipoxygenase (12/15LOX) enzyme is increased in pathologically affected frontal and temporal regions of Alzheimer's disease (AD) brains compared with controls. Herein, we measured 12(S)‐HETE and 15(S)‐HETE levels, products of 12/15LOX, in cerebrospinal fluid (CSF) of normal individuals, subjects with mild cognitive impairment (MCI) and AD. Compared with controls, there was a significant increase of both metabolites in CSF from AD and MCI, which correlated with lipid peroxidation and tau protein levels. These results suggest that the activation of this enzyme occurs early in the course of AD, before the onset of overt dementia, thereby implicating 12/15LOX‐mediated lipid peroxidation in the pathogenesis of AD. Ann Neurol 2005

[1]  J. Trojanowski,et al.  12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. , 2004, The American journal of pathology.

[2]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[3]  G. FitzGerald,et al.  The isoprostanes in biology and medicine , 2001, Trends in Endocrinology & Metabolism.

[4]  J. Trojanowski,et al.  Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.

[5]  John Q Trojanowski,et al.  Inflammatory hypotheses: novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? , 2000, Neurobiology of Aging.

[6]  A. Brash.  Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate* , 1999, The Journal of Biological Chemistry.

[7]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[8]  B. Thiele,et al.  The diversity of the lipoxygenase family , 1999, FEBS letters.

[9]  P. Maher,et al.  A Role for 12-lipoxygenase in Nerve Cell Death Caused by Glutathione Depletion , 1997, Neuron.

[10]  C. Clark,et al.  Performance of the Dementia Severity Rating Scale: A Caregiver Questionnaire for Rating Severity in Alzheimer Disease , 1996, Alzheimer disease and associated disorders.

[11]  J. Trojanowski,et al.  Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.

[12]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[13]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[14]  M. Nishiyama,et al.  Arachidonate 12-lipoxygenase is localized in neurons, glial cells, and endothelial cells of the canine brain. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  E. Kandel,et al.  Lipoxygenase metabolites of arachidonic acid as second messengers for presynaptic inhibition of Aplysia sensory cells , 1987, Nature.

[16]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[17]  D. Praticò,et al.  Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[18]  Z. Khachaturian,et al.  Fisher Symposium: Strategies for the Prevention of Alzheimer Disease—Overview of Research Planning Meeting III , 1996, Alzheimer Disease and Associated Disorders.